BioSpace

UniQure crashes as Huntington’s gene therapy shows less slowing of disease at 4 years

The results are nevertheless “unprecedented,” UniQure executives said on an investor call Tuesday, emphasizing that the updated natural history database used as the control group for the Phase 1/2 study of AMT-130 underestimates disease progression.

Por BioSpace

1 minuto de lectura
Compartir
UniQure crashes as Huntington’s gene therapy shows less slowing of disease at 4 years
UniQure crashes as Huntington’s gene therapy shows less slowing of disease at 4 years

¿Tiene noticias que compartir con el sector de eventos?

Envíe un comunicado de prensa o una noticia y llegue a miles de profesionales del sector de eventos.

Contáctenos→

Más en Health Tech

Perspectivas relacionadas